Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics, Inc. (GLUE)
:GLUE
Total Valuation
Monte Rosa Therapeutics has a market cap or net worth of $1.03B. The enterprise value is $259.48M.
Market Cap$1.03B
Enterprise Value$259.48M
Share Statistics
Monte Rosa Therapeutics has 65,117,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding65,117,760
Owned by Insiders12.93%
Owned by Institutions50.37%
Financial Efficiency
Monte Rosa Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -29.45%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-29.45%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee532.55K
Profits Per Employee-511.97K
Employee Count142
Asset Turnover0.17
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Monte Rosa Therapeutics is 51.6. Monte Rosa Therapeutics’s PEG ratio is 0.11.
PE Ratio51.6
PS Ratio6.78
PB Ratio2.30
Price to Fair Value2.30
Price to FCF13.50
Price to Operating Cash Flow42.20
PEG Ratio0.11
Income Statement
In the last 12 months, Monte Rosa Therapeutics had revenue of 75.62M and earned -72.70M in profits. Earnings per share was -0.98.
Revenue75.62M
Gross Profit67.50M
Operating Income-81.11M
Pretax Income-70.13M
Net Income-72.70M
EBITDA-72.99M
Earnings Per Share (EPS)-0.98
Cash Flow
In the last 12 months, operating cash flow was 149.14M and capital expenditures -4.12M, giving a free cash flow of 145.02M billion.
Operating Cash Flow149.14M
Free Cash Flow145.02M
Free Cash Flow per Share2.23
Dividends & Yields
Monte Rosa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.34
52-Week Price Change86.29%
50-Day Moving Average10.45
200-Day Moving Average6.38
Relative Strength Index (RSI)71.85
Average Volume (3m)1.05M
Important Dates
Monte Rosa Therapeutics upcoming earnings date is Mar 12, 2026, Before Open (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
Monte Rosa Therapeutics as a current ratio of 2.40, with Debt / Equity ratio of 15.34%
Current Ratio2.40
Quick Ratio2.40
Debt to Market Cap0.00
Net Debt to EBITDA2.49
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Monte Rosa Therapeutics has paid 2.57M in taxes.
Income Tax2.57M
Effective Tax Rate-0.04
Enterprise Valuation
Monte Rosa Therapeutics EV to EBITDA ratio is -4.54, with an EV/FCF ratio of 8.72.
EV to Sales4.38
EV to EBITDA-4.54
EV to Free Cash Flow8.72
EV to Operating Cash Flow7.89
Balance Sheet
Monte Rosa Therapeutics has $391.26M in cash and marketable securities with $40.17M in debt, giving a net cash position of $351.09M billion.
Cash & Marketable Securities$391.26M
Total Debt$40.17M
Net Cash$351.09M
Net Cash Per Share$5.39
Tangible Book Value Per Share$3.02
Margins
Gross margin is 96.47%, with operating margin of -107.26%, and net profit margin of -96.14%.
Gross Margin96.47%
Operating Margin-107.26%
Pretax Margin-92.74%
Net Profit Margin-96.14%
EBITDA Margin-96.52%
EBIT Margin-107.26%
Analyst Forecast
The average price target for Monte Rosa Therapeutics is $18.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$18.00
Price Target Upside26.58% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast1112.27%
EPS Growth Forecast―